These discoveries have led to the emergence of targeted drug treatment for melanoma such as inhibitors of BRAF, mitogen-activated protein kinase kinase 7 (MAP2K7, also known as MEK), and mitogen-activated protein kinase 1 (MAPK1, also known as ERK) [2, 4, 5]. Here, MAPK1 is linked to melanoma.